Metoprolol vs Carvedilol: Which Beta-Blocker Is Better?

The Quick Answer

Both metoprolol succinate (extended-release) and carvedilol are proven, guideline-recommended beta-blockers for heart failure with reduced ejection fraction (HFrEF). Carvedilol has additional alpha-1 blocking activity that provides vasodilation, making it slightly more effective in some analyses. However, both drugs significantly reduce mortality in HFrEF, and the choice often comes down to tolerability and side effect profile.

Side-by-Side Comparison

The COMET Trial: Head-to-Head Evidence

The COMET trial (2003) directly compared carvedilol vs. metoprolol tartrate (immediate-release) in 3,029 patients with HFrEF. Carvedilol reduced all-cause mortality by 17% more than metoprolol tartrate (34% vs. 40% mortality over 58 months). This was a significant finding that established carvedilol as the preferred beta-blocker in HFrEF for many cardiologists.

However, there is an important caveat: the trial used metoprolol tartrate (immediate-release), not metoprolol succinate (extended-release). The MERIT-HF trial showed that metoprolol succinate reduces mortality by 34% vs. placebo. Since COMET did not compare carvedilol to the extended-release formulation, the superiority of carvedilol over metoprolol succinate is not definitively established.

When to Prefer Carvedilol

• HFrEF with significant hypertension — carvedilol's alpha-1 blockade provides additional blood pressure lowering
• HFrEF with atrial fibrillation — carvedilol may provide better rate control
• Post-MI with HFrEF — carvedilol has strong evidence in this setting (CAPRICORN trial)
• When a single drug needs to address both HF and hypertension

When to Prefer Metoprolol Succinate

• COPD or mild-moderate asthma — metoprolol's beta-1 selectivity reduces bronchospasm risk
• Patients prone to hypotension or dizziness — metoprolol causes less vasodilation
• Once-daily dosing preference — metoprolol succinate is once daily; carvedilol is twice daily
• Diabetes — metoprolol's beta-1 selectivity better preserves hypoglycemia awareness

Important: Use the Right Formulation of Metoprolol

There are two formulations of metoprolol with very different clinical profiles:

• Metoprolol succinate (Toprol-XL) — Extended-release; once daily; proven in HFrEF (MERIT-HF); FDA-approved for HF
• Metoprolol tartrate (Lopressor) — Immediate-release; twice daily; NOT approved for HFrEF; used for hypertension, angina, and rate control

Using metoprolol tartrate instead of metoprolol succinate in heart failure is a common error. Only the succinate (extended-release) formulation has proven mortality benefit in HFrEF.

Cost Comparison

Both drugs are available as generics at similar cost. Generic metoprolol succinate typically costs $10–$25/month; generic carvedilol costs $10–$20/month. See our metoprolol cost guide and carvedilol cost guide for current pricing.

References

1. Poole-Wilson PA, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure (COMET). Lancet. 2003;362(9377):7-13.
2. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure (MERIT-HF). Lancet. 1999;353(9169):2001-2007.
3. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction (CAPRICORN). Lancet. 2001;357(9266):1385-1390.